4453 Total Publications
Hyperconnectivity Associated with Anosognosia Accelerating Clinical Progression in Amnestic Mild Cognitive Impairment
Chen, SS, Song, Y, Wu, HM, Ge, HL, Qi, WZ, Xi, Y, Wu, JY, Ji, YX, Chen, KX, Lin, XJ and Chen, J
2021; Journal Acs Chemical Neuroscience; vol. 14;
Self‐reported obstructive sleep apnea, amyloid and tau burden, and Alzheimer's disease time‐dependent progression
Bubu, OM, Umasabor‐Bubu, OQ, Turner, AD, Parekh, A, Mullins, AE, Kam, K, Birckbichler, MK, Mukhtar, F, Mbah, AK and Williams, NJ
2021; Journal Alzheimer's & Dementia; vol. 17; no. 2; pp. 226-245;
Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer's disease
Tissot, C, Benedet, AL, Therriault, J, Pascoal, TA, Lussier, FZ, Saha-Chaudhuri, P, Chamoun, M, Savard, M, Mathotaarachchi, SS, Bezgin, G, Wang, YT, Arias, JF, Rodriguez, JL, Snellman, A, Ashton, NJ, Karikari, TK, Blennow, K, Zetterberg, H, De Villers-Sidani, E, Huot, P, Gauthier, S, Rosa-Neto, P and Alzheimer's Dis, N
2021; Journal Alzheimers Research & Therapy; vol. 13; no. 1;
Tau-Atrophy Variability Reveals Phenotypic Heterogeneity in Alzheimer's Disease
Das, SR, Lyu, XY, Duong, MT, Xie, L, McCollum, L, Flores, R, DiCalogero, M, Irwin, DJ, Dickerson, BC, Nasrallah, IM, Yushkevich, PA, Wolk, DA and Alzheimer's Dis Neuroimaging, I
2021; Journal Annals of Neurology; vol. 90; no. 5; pp. 751-762;
Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview
Delaby, C, Teunissen, CE, Blennow, K, Alcolea, D, Arisi, I, Amar, EB, Beaume, A, Bedel, A, Bellomo, G, Bigot-Corbel, E, Bjerke, M, Blanc-Quintin, MC, Boada, M, Bousiges, O, Chapman, MD, DeMarco, ML, D'Onofrio, M, Dumurgier, J, Dufour-Rainfray, D, Engelborghs, S, Esselmann, H, Fogli, A, Gabelle, A, Galloni, E, Gondolf, C, Grandhomme, F, Grau-Rivera, O, Hart, M, Ikeuchi, T, Jeromin, A, Kasuga, K, Keshavan, A, Khalil, M, Kortvelyessy, P, Kulczynska-Przybik, A, Laplanche, JL, Lewczuk, P, Li, QX, Lleo, A, Malaplate, C, Marquie, M, Masters, CL, Mroczko, B, Nogueira, L, Orellana, A, Otto, M, Oudart, JB, Paquet, C, Paoletti, FP, Parnetti, L, Perret-Liaudet, A, Peoc'h, K, Poesen, K, Puig-Pijoan, A, Quadrio, I, Quillard-Muraine, M, Rucheton, B, Schraen, S, Schott, JM, Shaw, LM, Suarez-Calvet, M, Tsolaki, M, Tumani, H, Udeh-Momoh, CT, Vaudran, L, Verbeek, MM, Verde, F, Vermunt, L, Vogelgsang, J, Wiltfang, J, Zetterberg, H and Lehmann, S
2021; Journal Alzheimers & Dementia; vol. 12;
Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease
Libiger, O, Shaw, LM, Watson, MH, Nairn, AC, Umana, KL, Biarnes, MC, Canet-Aviles, RM, Jr, CRJ, Breton, YA, Cortes, L, Chelsky, D, Spellman, DS, Baker, SA, Raghavan, N, Potter, WZ, Alzheimers Dis Neuroimaging, I, Fdn Natl Inst Hlth Fnih, B and Longitudinal, CSFPP
2021; Journal Alzheimers & Dementia;
The protective gene dose effect of the APOE ε2 allele on gray matter volume in cognitively unimpaired individuals
Salvadó, G, Ferreira, D, Operto, G, Cumplido-Mayoral, I, Arenaza-Urquijo, EM, Cacciaglia, R, Falcon, C, Vilor-Tejedor, N, Minguillon, C, Groot, C, van der Flier, WM, Barkhof, F, Scheltens, P, Ossenkoppele, R, Kern, S, Zettergren, A, Skoog, I, Hort, J, Stomrud, E, van Westen, D, Hansson, O, Molinuevo, JL, Wahlund, LO, Westman, E and Gispert, JD
2021; Journal Alzheimers Dement;